Madrigal's MGL-3196 shows sustained benefit in mid-stage NASH study; shares up 40% premarket
May 31, 2018 7:19 AM ET|About: Madrigal Pharmaceutica... (MDGL)|By: Douglas W. House, SA News Editor
A Phase 2 clinical trial assessing Madrigal Pharmaceuticals' (NASDAQ:MDGL) MGL-3196 in patients with non-alcoholic steatohepatitis (NASH) met the primary endpoint at week 12 and demonstrated a sustained treatment benefit at week 36.
39% of the responders at week 12 experienced complete resolution of NASH at week 36 compared to 6% for placebo (p=0.001). Fibrosis was resolved in half the patients.
Mean liver fat reduction was 37.0% in the treatment group compared to 8.9% for placebo.
No new safety signals were observed.
A larger Phase 3 with a longer treatment period is next up.
Management will host a conference call this morning at 8:30 am ET to discuss the results.
Shares are up 40% premarket on light volume.
Previously: Madrigal Pharma's lead candidate successful in mid-stage NASH study; shares ahead 45% premarket (Dec. 6, 2017)
Market Data 
Markets 
AI
